Health and Human Services officials said this week they are pressing manufacturers and pharmacies to keep estradiol patches on shelves after a surge in demand followed the removal of long-standing “black box” warnings on menopause hormone therapy.
In a September 17 post, HHS said Secretary Robert F. Kennedy Jr. met with manufacturers, distributors, physicians and pharmacy leaders “to better understand the challenges women are having.” The department said it is working to increase reliable access to estradiol patches and to educate physicians on other options and how to prescribe them.
American women were denied hormone therapy for 20 years over outdated warnings. HHS removed the “black box” label last year, and demand has skyrocketed.
This week, @SecKennedy met with manufacturers, distributors, physicians, and pharmacy leaders to better understand the… pic.twitter.com/FN9rfcJtoB
— HHS (@HHSGov) September 17, 2026
The meeting comes after months of reports that women cannot fill the patches they already use. The Food and Drug Administration says supply has nearly doubled in a year and that patches “remain available.”
Hospital pharmacists and patients describe a different counter: specific brands and doses missing for weeks.
Why The Patches Are Hard to Find
Estradiol transdermal patches deliver estrogen through the skin to treat menopause symptoms. They are applied once or twice a week, depending on the product.
Demand rose after HHS and the FDA moved in November 2025 to strip boxed warnings about cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy labels.
The Dallas Express reported that decision when it was announced. The FDA approved the first batch of revised labels in February 2026.
On September 3, the FDA said it was “aware of reports of patients having difficulty readily accessing their usual estradiol transdermal patches due to increased demand” and that it is working with all six manufacturers.
Over the last year, the agency said, the supply of FDA-approved estradiol patches has nearly doubled. Manufacturers are adding shifts, expanding capacity, increasing batch sizes and prioritizing patch production.
The agency has not placed estradiol patches on its official drug-shortage list. The American Society of Health-System Pharmacists has. ASHP’s shortage bulletin has listed multiple estradiol transdermal products from Sandoz, Noven, Zydus, Amneal and others, with some strengths on back order and no estimated release date. The Pediatric Endocrine Society cited ASHP’s listing as early as March.
That gap matters.
FDA shortage status is based largely on manufacturer reports and whether total supply meets historical demand. ASHP’s list is driven by what hospitals and pharmacies actually cannot obtain. A woman can read a federal update saying patches remain available while her pharmacy has none of her brand.
HealthVerity data reported by CNBC showed estrogen-patch prescriptions up 162% over two years. A May Midi survey of more than 8,000 women, cited by USA TODAY, found nearly half of women on hormone therapy were having trouble filling patch prescriptions.
What The Patch Does
The FDA says menopausal hormone therapies are approved to treat hot flashes and night sweats. Some products are also approved to help prevent bone loss.
A patch releases estradiol into the bloodstream without first passing through the digestive tract. Brands and generics include once-weekly products such as Climara and twice-weekly products such as Vivelle-Dot and Dotti. Women who still have a uterus generally need a progestogen with systemic estrogen to reduce the risk of endometrial cancer.
The FDA kept the boxed warning for endometrial cancer on systemic estrogen-alone products.
The 2022 position statement of The Menopause Society (formerly NAMS) says oral and transdermal estrogen can both relieve vasomotor symptoms. Transdermal estradiol is often preferred for women at higher risk of blood clots because it avoids a first-pass liver effect.
What Happens When The Supply Runs Out
The FDA’s own advice is clear: do not stop or change the medication without talking to a clinician.
That warning exists because symptoms can return quickly. Official labeling for estradiol transdermal systems states that if a woman stops using the patch or misses a scheduled change, she may have spotting or bleeding and a recurrence of symptoms.
The Menopause Society’s 2022 hormone-therapy statement reports that vasomotor symptoms return in about 50% of women when hormone therapy is discontinued. There is no consensus on whether stopping abruptly or tapering is better.
Women forced onto a gap in treatment commonly describe the same cluster that brought them to the patch in the first place: hot flashes, night sweats, sleep disruption, mood changes and vaginal dryness. Those are the symptoms the product is approved to treat. They are not a separate disease caused by the shortage. They are the underlying condition coming back.
Some patients can switch brands or doses. Others cannot. Pharmacies do not stock every strength. Insurance often covers one product and rejects another.
Compounded estrogen is sometimes offered as a workaround; it is not an FDA-approved equivalent, and clinicians at systems such as UCHealth have advised against treating the shortage by substituting compounded estrogen without medical guidance.
The Two-Decade Restriction
The current scramble is the aftershock of a 2002 study and a 2003 label.
In July 2002, the National Heart, Lung, and Blood Institute stopped the Women’s Health Initiative trial of combined estrogen plus progestin after an average 5.2 years. The principal results, published in JAMA, found higher rates of coronary heart disease, stroke, pulmonary embolism and invasive breast cancer, and lower rates of hip fracture and colorectal cancer. The average participant was 63, older than the typical woman starting treatment at menopause.
In January 2003, the FDA required boxed warnings on estrogen products. Prescriptions fell.
HHS now describes that era as two decades in which “American women were denied hormone therapy” over outdated warnings. The agency’s 2025 review concluded the broad boxed language on cardiovascular disease, breast cancer and probable dementia should come off, with treatment discussions individualized, especially for women younger than 60 or within 10 years of menopause.
That policy shift is what manufacturers say they were not staffed to meet.
What Washington Says It Is Doing Now
The FDA’s September update lists concrete steps: expedited review of manufacturer submissions to increase supply, added production shifts, larger batches, new equipment and lines, and priority for estradiol patches.
HHS’s September 17 message added a second track: Kennedy’s meeting with the supply chain and a push to teach physicians how to prescribe alternatives when a preferred patch is out.
Companies including Amneal, Sandoz, Noven, Bayer, Zydus and Viatris sell estradiol patches in the United States. Bayer has said it expects temporary constraints on one Climara dose into early 2027.
None of that puts a date on when a woman in Dallas or Fort Worth can walk into a neighborhood pharmacy and fill the same box she filled last year.
What Patients Are Told to Do
Until supply catches demand, federal guidance is practical and limited:
- Ask the pharmacist to locate another FDA-approved estradiol patch that can be substituted.
- Call the prescriber before stopping. Gels, sprays, oral estradiol and other approved products may be appropriate for some patients.
- Check back. Inventory is moving in fits.
- Report local shortages to the FDA at [email protected].
HHS called this week “just the beginning of the conversation.” For women already on a patch, the conversation is secondary. The immediate problem is whether the next refill exists.
